NPCE News

12 IPOs raised $3.7 billion this past week, led by software maker UiPath (PATH), which raised more than $1 billion in its public debut. The pipeline remained active, with 11 IPOs and one direct listing submitting initial filings. SPAC activity continued to decline, with no pricings for the first week ever in 2021 and just four new filings. The largest deal...read more

NeuroPace, which makes a brain-responsive neuromodulation system for drug-resistant epilepsy, is expected to begin trading on the Nasdaq on Thursday. The company raised $102 million in its IPO by offering 6.0 million shares at $17, the high end of the range of $15 to $17. The company offered 0.7 million more shares than anticipated. At pricing, NeuroPace commands a fully...read more

NeuroPace, which makes a brain-responsive neuromodulation system for drug-resistant epilepsy, raised $102 million by offering 6 million shares at $17, the high end of the price range of $15 to $17. The company offered 0.7 million more shares than anticipated. NeuroPace states that its novel and differentiated RNS System is the first and only commercially available,...read more

Updated Monday, 4/19. 11 IPOs are scheduled to raise a total of $3.6 billion in the week ahead, led by software maker UiPath (PATH). The largest IPO of the week, UiPath (PATH) plans to raise $990 million at a $26.0 billion market cap. The company provides software that identifies automation opportunities across organizations....read more